BioSpace News Archive

As the name suggests, next-generation antibody therapeutics is characteristic of advanced antibody therapeutics.

Polycystic kidney disease (PKD) is a genetic disease that affects the kidneys and other organs by causing uncontrolled growth of cysts in the kidney, eventually leading to kidney failure.

Amolyt Pharma announced positive efficacy and safety data from the first cohort of its ongoing Phase 2a study of AZP-3601 in patients with hypoparathyroidism at the American Society for Bone and Mineral Research 2022 Annual Meeting, which is being held September 9-12 in Austin, TX.

he demand within the global preclinical imaging market is slated to increase over the times to come by.

The preimplantation genetic testing is an increasingly go-to option for identifying genetic birth effects in children.

Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that Dror Bashan, the Company’s President and Chief Executive Officer, will present in person on Wednesday, September 14, 2022 at 11:00 a.m. Eastern Daylight Time (EDT) at the H.C. Wainwright 24th Annual Global Investment Conference.

Oxurion NV a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced that it will participate in two upcoming conferences.

The Board of Directors for Plastomics Inc., a biotechnology company developing a novel trait delivery platform for the agricultural sector, has named Tania Seger as its new Chief Executive Officer and Member of the Board.

The American Association of Orthopaedic Surgeons issued formal comments to the Centers for Medicare & Medicaid Services on the agency’s proposed payment policy changes for Calendar Year 2023.

The global Next Generation Surgical Robotics market size was estimated at USD 2.6 billion in 2021 and is expected to surpass around USD 10.8 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 35.14% during the forecast period 2022 to 2030.